Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response

該当なし 完了 NCT03175068

概要

Many patients with Major Depressive Disorder (MDD) and generalized Social Anxiety Disorder (gSAD) are treated with cognitive behavioral therapy (CBT) but few have meaningful improvement. MDD and gSAD are diseases of brain dysfunction that manifest as impaired emotion regulation; CBT teaches emotion regulation strategies but how it works in the brain remains largely unknown. Individual differences in brain function related to emotion regulation may make some patients better suited for CBT and CBT may remedy the brain dysfunction that underlies these disorders. This project will compare CBT with a placebo psychotherapy (i.e., supportive therapy) in MDD and gSAD to test, validate, and refine brain-based markers and examine mechanisms of change to examine how CBT works and for whom.

Changes in Symptom Severity From Baseline to Week 12 Between Treatment Arms

baseline and week 12 · units on a scale

Baseline Brain Activity During Emotion Regulation Differences Between Controls and Patients

baseline · arbitrary units

Comparisons Between Emotion Regulation Task Brain Activity at Baseline and After Completing Therapy (12 Weeks).

baseline and 12 weeks · arbitrary units

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• CBT+ for Depression — University of Wisconsin, Madison
• Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
• Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
• Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
• A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
• Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital

すべての治験